Fact Check Friday: Biopharmaceutical company communications with payers

Today, we’re examining how and what biopharmaceutical companies communicate with payers about a medicine prior to its approval by the U.S. Food and Drug Administration (FDA). MYTH:...
Read More
Phased-in approach offers best hope for FDA’s proposed quality metrics program

In July 2015, the U.S. Food and Drug Administration (FDA) issued draft guidance for industry requiring manufacturers to provide certain manufacturing data on an annual basis. The FDA’s Center for...
Read More
Research doesn’t end on a medicine’s approval

Research is a critical part of the development of new medicines, but it doesn’t stop once the medicine is approved by the U.S. Food and Drug Administration (FDA). In fact, that’s when post-approval...
Read More